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Glial cell line-derived neurotrophic factor
Divalent metal transporter 1 with iron
responsive element
Iron regulatory protein 1Iron accumulation is observed in the substantia nigra of patients with Parkinson's disease. However, it is
unknown whether neurotrophic factors, brain-derived neurotrophic factor (BDNF) and glial cell line-derived
neurotrophic factor (GDNF) participate in the modulation of neuronal iron metabolism. Here, we investigated
the effects and underlyingmechanisms of BDNF and GDNF on the iron inﬂux process in primary cultured ventral
mesencephalic neurons. 6-hydroxydopamine-induced enhanced ferrous iron inﬂux via improper up-regulation
of divalent metal transporter 1 with iron responsive element (DMT1 + IRE) was consistently relieved by BDNF
and GDNF. Both themRNA and protein levels of DMT1+ IRE were down-regulated by BDNF or GDNF treatment
alone.We further demonstrated the involvement of iron regulatory protein 1 (IRP1) in BDNF- andGDNF-induced
DMT1+ IRE expression. Extracellular-regulated kinase 1/2 (ERK1/2) and Akt were activated and participated in
these processes. Inhibition of ERK1/2 and Akt phosphorylation abolished the down-regulation of IRP1 and DMT1
+ IRE induced by BDNF and GDNF. Taken together, these results show that BDNF and GDNF ameliorate iron
accumulation via the ERK/Akt pathway, followed by inhibition of IRP1 and DMT1 + IRE expression, which
may provide new targets for the neuroprotective effects of these neurotrophic factors.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is a neurodegenerative disorder character-
ized in its late phase by the sustained loss of dopaminergic (DAergic)
neurons in the substantia nigra pars compacta (SNpc) [1–3]. Extensive
evidence has shown that selective high levels of iron and oxidative stress
in the SNpc play a key role in PDpathogenesis [4–8]. Excess iron can gen-
erate high levels of reactive oxygen species (ROS) through the Fenton
reaction by acting on the dopamine metabolite H2O2 [9–11]. IronF, brain-derived neurotrophic
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this work.homeostasis is achieved by several iron trafﬁcking proteins [12,13]. We
previously reported that the aberrant regulation of divalent metal trans-
porter 1 (DMT1/Nramp2/SLC11A2) by the iron responsive element (IRE,
DMT1+ IRE)may account for the abnormal iron accumulation in the SN
of PD animalmodels [14,15], which agreeswith a study showing that in-
creases in DMT1 were associated with degeneration of DAergic neurons
in PD patients andwere a commonphenomenon in animalmodels of PD
[16]. Thus, DMT1 may serve as a promising molecular target for thera-
peutic interventions that would slow PD progression [16].
Autopsy results of PD patients showed marked reductions of
brain-derived neurotrophic factor (BDNF) mRNA and protein levels
in the striatum and SN compared with other brain regions [17–19].
The replenishment of neurotrophic factors (NTFs), such as BDNF
and glial cell line-derived neurotrophic factor (GDNF), to an appropriate
site of action may provide important neuronal support in PD [20,21].
BDNF and GDNF, the most often studied neurotrophins related to
neurodegeneration, belong to two different families of NTFs. By binding
to their high-afﬁnity receptors tyrosine kinase receptor B (TrkB) and
GDNF family receptor α (GFRα), respectively, BDNF and GDNF could
promote the survival and morphological differentiation of midbrain
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organotypic culture, BDNF treatment after 6-hydroxydopamine
(6-OHDA) lesion has been reported to not only improve cell survival
but also transcriptionally up-regulate tyrosine hydroxylase (TH) mRNA
expression [25]. Other investigations have shown that GDNF can prevent
the death of dopamine neurons and promote functional recovery in
1-methyl-4-phenyl-l 1, 2, 3, 6- tetrahydropyridine (MPTP)-treated
rodent and nonhuman primate PD models in vivo [28–30]. However,
little is known about the ability of these NTFs to regulate trace metal
ion metabolism, such as iron, in the central nervous system (CNS).
In this report, we tested the hypothesis that BDNF and GDNF could
protect primary cultured ventral mesencephalic (VM) neurons from
6-OHDA induced iron accumulation by regulating the iron importer
DMT1 + IRE and possibly its post-transcriptional activator, iron regula-
tory protein 1 (IRP1). Utilizing pharmacological approaches, we also
aimed to elucidate the involvement of intracellular pathways in this
process.
2. Materials and methods
2.1. Materials
All procedures were performed in accordance with the National In-
stitute of Health Guide for the Care and Use of Laboratory Animals and
approved by the Animal Ethics Committee of Qingdao University.
Dulbecco′s modiﬁed Eagle′s medium Nutrient Mixture-F12 (DMEM/
F12) and B27 were obtained from Gibco (Grand Island, NY, USA).
Recombinant BDNF, GDNF and 6-OHDA were obtained from Sigma
(St Louis, MO, USA). The speciﬁc phosphatidylinositol 3-kinase
(PI3K) inhibitor LY294002 andMEK inhibitor PD98059 were purchased
from Beyotime (Jiangsu, China). The primary antibodies rabbit anti-
DMT1 + IRE, rabbit anti-transferrin receptor 1 (TfR1), and rabbit anti-
IRP1 were obtained from Alpha Diagnostic (San Antonio, TX, USA);
rabbit anti-ERK1/2, rabbit anti-phospho-ERK1/2 (T202/Y204), rabbit
anti-Akt and rabbit anti-phospho-Akt (Ser473) were obtained from
Cell Signaling Technology (Beverly, MA, USA); and mouse anti-TH was
obtained from Sigma (St Louis, MO, USA). All other chemicals and re-
gentswere of the highest grade available from local commercial sources.
2.2. VM neuron culture and pharmacological treatments
Primary rat VM neuron cultures were obtained from embryonic day
14–15 Wistar rats as described previously by our laboratory [31,32].
Brieﬂy, VM tissues were dissected from embryonic day 14–15 rat brains
and dissociatedmechanically. After centrifugation, cells were suspended
in DMEM/F12 supplemented with 2% B27, 100 U/ml penicillin, and
100 μg/ml streptomycin and seeded on poly-D-lysine-coated cover
slips or 12-well culture plates at a density of 6 × 105 cells/ml or 1.5 ×
106 cells/ml, respectively. Cells weremaintained at 37 °C in a humidiﬁed
atmosphere of 5% CO2 and 95% air for 18 h, and then, the medium was
changed. Cultures were replenished with fresh medium 3 days later
and used at 6 days in vitro (DIV). Neuron purity was approximately
96% based on immunoﬂuorescence staining with the speciﬁc neuron
marker MAP2. Approximately 2% of the neurons exhibited TH positivity,
indicating DAergic neurons (data not shown).
Neuronal treatments with pharmacological agents were performed
without B27 supplement. For both BDNF and GDNF, 10 ng/ml is a
commonly used concentration that exerts neuroprotective effects
in vitro [33–37]. A concentration of 10 μM 6-OHDA was used based on
our previous study, which does not cause signiﬁcant cell loss [31].
2.3. Calcein loading of cells and ferrous iron inﬂux assay
The ferrous iron inﬂux into neurons was determined by measuring
the quenching of calcein ﬂuorescence as previously described by our
laboratory [14,38]. Cells seeded onto coverslips were incubated withcalcein-AM (0.5 μM ﬁnal concentrations) in Hepes-buffered saline
(HBS, 10 mM Hepes, 150 mM NaCl, pH 7.4) for 30 min at 37 °C. After
three washes with HBS, the cells were perfused with 0.5 mM ferrous
iron (ferrous sulfate in ascorbic acid solution, 1:44 molar ratio, pH 6.0)
to maintain extracellular stabilization of the iron concentration. Then,
calcein ﬂuorescence was recorded using an Olympus FV500 confocal
microscope at 488 nm excitation and 525 nm emission wavelengths,
and ﬂuorescence intensitywasmeasured every 3min for 10 repetitions.
The ﬂuorescence intensity representing the mean value of 35–40
separate cells from four separate ﬁelds was monitored at × 20 magniﬁ-
cation at each time point and processed with Fluoview 5.0 Software.
2.4. Western blots
After three washes with cold PBS, the cells were lysed with lysis
buffer. Insoluble material was removed by centrifugation. A total of
20–40 μg of protein was separated using 10% SDS-polyacrylamide gels
and then transferred onto PVDF membranes. After 2 h of blocking
with 10% non-fatmilk at room temperature, themembranes were incu-
bated with primary antibodies, including a DMT1 + IRE antibody
(1:800), IRP1 (1:1000), TfR1 (1:800), Akt, phospho-Akt, ERK1/2 and
phospho-ERK1/2 (1:1000) overnight at 4 °C. β-actin was detected by
an anti-β-actin monoclonal antibody (1:8000) according to a similar
procedure to ensure equal samples of protein. Membranes were then
incubated in peroxidase-conjugated secondary anti-rabbit secondary
antibody (1:10,000, Santa Cruz Biotechnology, Santa Cruz, CA) at
room temperature for 1 h, and excess IgG was removed with TBST
washes. Cross-reactivity was visualized using ECL western blotting de-
tection reagents and then analyzed with scanning densitometry by a
UVP Image System.
2.5. Total RNA extraction and quantitative real-time PCR
Total RNA was isolated from neurons treated as described above
using the Trizol Reagent (Invitrogen) according to themanufacturer's in-
structions. Then, 2 μg of total RNAwas reversed transcribed in a 20 μl re-
action with oligo-dT primers using a reverse-transcription system
(Promega). Quantitative real-time RCR was used to detect the changes
in DMT1 + IRE. A TaqMan probe and primers were designed with re-
spect to the sequences using the default settings of Primer Express 2.0
(PE Applied Biosystems). Each set of primers was used with a TaqMan
probe labeled at the 5’-endwith the 6-carboxyﬂuorescein (FAM) report-
er dye and at the 3’-end with the 6-carboxy-tetramethylrhodamine
(TAMRA) quencher dye. The following primers and probes were
employed. DMT1 + IRE: sense: 5′-TGG CTG TCA CGA GTG CTT ACA-3′,
antisense: 5′-CCA TGG CCT TGG ACA GCT ATT-3′, probe: 5′-TTA CCC
TGT AGC ATT AGG CAG CAC C-3′; GAPDH: sense: 5′-CCC CCA ATG TAT
CCG TTG TG-3′, antisense: 5′-GTA GCC CAG GAT GCC CTT TAG T-3′,
probe: 5′-TCT GAC ATG CCG CCT GGA GAA ACC-3′.
Ampliﬁcation and detection were performed with the following
conditions: an initial hold at 95 °C for 10 s, followed by 35 cycles at
95 °C for 5 s and 60 °C for 45 s.
2.6. Double immunoﬂuorescence labeling
Primary cultured VM neurons were detected with an anti-MAP2 an-
tibody. Brieﬂy, cells were ﬁxed with 4% paraformaldehyde followed by
blocking with PBS containing 0.3% Triton X-100 and 10% normal goat
serum. Then, cells were incubated with primary antibodies, including
mouse anti-MAP2 (1:500), rabbit anti-phospho-ERK1/2 (1:200) or rab-
bit anti-phospho-Akt (1:200) overnight at 4 °C. The cells were then
washed with PBS and incubated for 1 h with the secondary antibodies
Alexa Fluor® 488 goat anti-mouse IgG (H + L) (1:500) and Alexa
Fluor® 555 goat anti-rabbit IgG (H + L) (1:500) at room temperature.
After rinsing with PBS, the cells were examined using a Fluoview
FV500 laser confocal scanningmicroscope. Control coverslips incubated
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2.7. Statistical analysis
The results are presented as the mean ± S.E.M. An unpaired
Student's t test was performed to analyze the differences between two
groups. One-way analysis of variance (ANOVA), followed by the
Student–Newman–Keuls test, was used to compare differences be-
tween three or more groups. Iron inﬂux studies were analyzed using
two-way ANOVA. A probability of P b 0.05 indicated statistical
signiﬁcance.
3. Results
3.1. BDNF and GDNF attenuated 6-OHDA-induced ferrous iron inﬂux in
primary cultured VM neurons
The ﬂuorescent dye calcein was used to monitor the ferrous iron
inﬂux of VM neurons with 0.5 mM ferrous iron perfusion. The ﬂuo-
rescence intensity declined gradually inside cells, indicating a trans-
membrane ferrous iron inﬂux. In agreement with our data in
MES23.5 cells [15], in 10 μM 6-OHDA-treated cells, more rapid ﬂuo-
rescence quenching and a signiﬁcant decrease in the ﬂuorescence in-
tensity occurred compared with controls. However, pretreatment
with 10 ng/ml BDNF or 10 ng/ml GDNF for 4 h fully blocked this process
and produced a ﬂuorescence intensity similar to the control levels
(Fig. 1A,B), indicating that BDNF and GDNF suppress the increased
ferrous iron inﬂux caused by 6-OHDA.
3.2. BDNF and GDNF down-regulated DMT1 + IRE expression in primary
cultured VM neurons
DMT1 is the importer of ferrous iron, and previous research has
shown that the brain appears to express a higher amount of DMT1
with IRE compared with DMT1 without IRE [39]. In the present study,
VM neurons were incubated with a vehicle, BDNF (10 ng/ml), GDNF
(10 ng/ml), and 6-OHDA (10 μM) for 24 h or incubated with BDNF
(10 ng/ml) or GDNF (10 ng/ml) for 4 h prior to 6-OHDA (10 μM) treat-
ment for another 24 h, and the protein andmRNA levels of DMT1+ IRE
were determined. As shown in Fig. 2A and B, singular BDNF or GDNF
treatment suppressed DMT1 + IRE protein levels to nearly 26% or 21%Fig. 1. BDNF, GDNF attenuated iron inﬂux in 6-OHDA-treated VM neurons. Ferrous iron inﬂux i
lular iron levels. When 0.5 mM ferrous iron was used to perfuse the cells, a more rapid decreas
indicating increased ferrous iron inﬂux in 6-OHDA-treated cells. The ﬂuorescence intensity wa
ANOVA, F = 43.620, P b 0.05, 6-OHDA group compared with control; P b 0.05, BDNF + 6-
ANOVA, F = 34.744, P b 0.05, 6-OHDA group compared with control; P b 0.05, GDNF + 6-O
mean value of 35–40 separate cells monitored at × 20 magniﬁcation at each time point. Data abelow the control level, respectively. DMT1 + IRE protein levels in
6-OHDA-treated VM neurons were up-regulated 1.5-fold compared
with the control level. However, pretreatment with BDNF fully
blocked 6-OHDA-induced DMT1 + IRE up-regulation. Similar effects
were observed in the cells pretreated with GDNF. In addition, no
signiﬁcant differences were observed in the protein expression of
DMT1 + IRE between the BDNF and GDNF groups (Fig. 2C).
To further investigate whether this altered expression of
DMT1+ IRE proteinwas due to the change in DMT1+ IREmRNA tran-
scription, quantitative real-time PCR was conducted. GAPDH mRNA
showed stable expression in the different groups (data not shown).
BDNF and GDNF incubation down-regulated DMT1 + IRE mRNA levels
to 50% and 40% of the basal levels, respectively, and thus fully abolished
the 6-OHDA-induced up-regulation of DMT1 + IRE (Fig. 2D,E). These
results indicated that both BDNF and GDNF could exert suppressive ef-
fects on DMT1 + IRE expression at both the protein and mRNA levels.3.3. BDNF- and GDNF-induced down-regulation of DMT1 + IRE was IRE/
IRP dependent in primary cultured VM neurons
We next investigated whether BDNF and GDNF modulate
DMT1 + IRE directly or produce an indirect outcome by targeting
other molecules. IRPs register cytosolic iron concentrations and post-
transcriptionally regulate the expression of iron metabolism genes,
such as DMT1+ IRE and TfR1, by binding to the IRE in the 3’ untranslat-
ed region (UTR). IRP1 is much more abundant than IRP2 in most cells
and tissues, and IRP1 commonly makes a greater contribution to IRE-
binding activity than IRP2 [40]. Therefore, we tested the effects of
BDNF and GDNF on IRP1 levels. We observed approximately 19% and
17% down-regulation of IRP1 protein levels in BDNF (10 ng/ml)- and
GDNF (10 ng/ml)-treated VM neurons, respectively. As demonstrated
previously in 6-OHDA-treatedMES23.5 cells [15], 10 μM6-OHDA treat-
ment up-regulated IRP1 protein levels by 20% in primary cultured VM
neurons. As expected, BDNF and GDNF (10 ng/ml) fully abolished the
6-OHDA-induced up-regulation of IRP1 (Fig. 3A,B). Additionally, no
changes were observed between the BDNF and GDNF groups (Fig. 3C).
To further conﬁrm that BDNF and GDNF participated in IRP1 regula-
tion, we detected the expression of TfR1 after BDNF and GDNF treat-
ment. Similar to the regulation of DMT1 + IRE induced by BDNF and
GDNF, the results showed that BDNF or GDNF treatment suppressed
the basal levels of TfR1 expression, and pretreatment with these NTFs
fully blocked the 6-OHDA-induced TfR1 up-regulation (Fig. 4).n VMneurons was determined by quenching calcein ﬂuorescence, an indicator of intracel-
e in ﬂuorescence intensity occurred in cells treated with 6-OHDA compared with controls,
s restored to control levels when cells were pretreated with 10 ng/ml BDNF (A, two-way
OHDA group compared with 6-OHDA group) and 10 ng/ml GDNF for 4 h (B, two-way
HDA group compared with 6-OHDA group). The ﬂuorescence intensity represents the
re presented as the mean ± S.E.M. of four independent experiments.
Fig. 2. BDNF and GDNF down-regulated DMT1+ IRE expression and abolished 6-OHDA-induced DMT1+ IRE upregulation in VM neurons. A and B: DMT1+ IRE protein levels were up-
regulated in 6-OHDA-treated primary culturedDIV6VMneurons, which could be fully abolished by pretreatmentwith BDNF or GDNF for 4 h prior to 6-OHDA incubation. Singular BDNF or
GDNF treatment down-regulated DMT1 + IRE levels. β-actin was used as a loading control. Data are presented as the ratio of DMT1 + IRE to β-actin. C: No signiﬁcant differences were
observed in the expression of DMT1+ IRE between the BDNF and GDNF groups. D and E: DMT1mRNA levels were up-regulated in the 6-OHDA group and restored to control levels with
10 ng/ml BDNF or 10 ng/ml GDNF pretreatment. Down-regulation of DMT1 + IRE mRNA was observed when VM cultures were subjected to BDNF or GDNF. Data are presented as fold
changes in mRNA expression of treatment vs. control. Each bar represents the mean ± S.E.M. of four independent experiments. ⁎P b 0.05, ⁎⁎P b 0.01, compared with control, #P b 0.05,
##P b 0.01, compared with the 6-OHDA group.
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3.4. BDNF- and GDNF- induced activation of the MEK/ERK and PI3K/Akt
signaling pathways in primary cultured VM neurons
BDNF binds to its high afﬁnity receptor TrkB, and GDNF speciﬁcally
binds to GFRα, both of which can induce the activation of the MEK/
ERK andPI3K/Akt signalingpathways, which are important for neuronal
survival [41,42]. The activation of ERK1/2 and Akt depends on their
phosphorylation; hence, phospho-speciﬁc antibodies can be used to as-
sess their relative activities. VMneuronswere incubatedwith BDNF andFig. 3. BDNF and GDNF abolished 6-OHDA-induced IRP1 upregulation in VM neurons. A, B: P
prevented the 6-OHDA-induced up-regulation of IRP1. A decline in IRP1 expression was obse
were observed between BDNF and GDNF treatment. β-actin was used as a loading contro
⁎⁎P b 0.01, compared with control, ##P b 0.01, compared with the 6-OHDA group.GDNF for the indicated periods (0, 0.5, 1, 2 and 4 h) and then collected
for western blot analysis of phospho-ERK1/2 and phospho-Akt. As
shown in Fig. 5A and E, we determined that ERK1/2 phosphorylation
occurred in a time-dependent manner, with maximum activation
observed within 0.5 h in both the BDNF- and GDNF-treated groups.
However, the activation was more dramatic (up to 7-fold greater) in
BDNF-treated cells compared with GDNF-treated cells. Phospho-ERK1/2
levels remained above basal levels after 4 h of treatment in the BDNF
group; however, phospho-ERK1/2 had returned to basal levels in the
GDNF group. Akt also underwent time-dependent phosphorylation in
response to BDNF and GDNF treatment in VM neurons (Fig. 5C,G). Maxi-
mum activation was achieved within 30 min of treatment in both theretreatment with BDNF (A) or GDNF (B) for 4 h prior to 6-OHDA incubation effectively
rved in BDNF and GDNF (10 ng/ml) alone treatment groups. C: No signiﬁcant differences
l. Each bar represents the mean ± S.E.M. of four independent experiments. ⁎P b 0.05,
Fig. 4.BDNF andGDNF abolished 6-OHDA-induced TfR1 upregulation inVMneurons. TfR1 protein levelswere up-regulated in 6-OHDA-treated primary culturedVMneurons, and this up-
regulationwas fully abolished bypretreatmentwith BDNF andGDNF for 4 h prior to 6-OHDA incubation. BDNForGDNF treatment alone caused thedown-regulation of TfR1 levels.β-actin
was used as a loading control. Each bar represents the mean ± S.E.M. of four independent experiments. ⁎⁎P b 0.05, ##P b 0.01, compared with control.
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tude of Akt activationwas signiﬁcantly lower in the GDNF-treated groups
compared with the BDNF-treated groups. No changes in the total ERK1/2
and total Akt levels were observed at any time point.
We also examined the expression of the phosphorylated forms of
ERK1/2 and Akt at the cellular level. BDNF and GDNF treatment for
30min increased phospho-ERK1/2 and phospho-Akt immunoreactivity
in MAP2-positive neurons. PD98059 (5 μM), an inhibitor of MEK, and
LY294002 (2.5 μM), an inhibitor of PI3K, were able to block these effects
(Fig. 5B,D,F,G).
3.5. MEK/ERK and PI3K/Akt pathways participate in the BDNF- and GDNF-
induced down-regulation of IRP1 and DMT1 + IRE
To further explore thepossibility of the participation of theMEK/ERK
and PI3K/Akt pathways in the regulation of IRP1 and DMT1 + IRE ex-
pression, we measured the effects of the speciﬁc inhibitors PD98059
(5 μM) and LY294002 (2.5 μM) on the protein and mRNA levels of
IRP1 and DMT1 + IRE. Primary cultured VM neurons were pretreated
with speciﬁc inhibitors for 0.5 h, and then, 10 ng/ml BDNF or GDNF
were added for another 24 h. As shown in Fig. 6A and D, pretreatment
with the inhibitors fully blocked BDNF- and GDNF-mediated down-
regulation of IRP1, suggesting that the ERK1/2 and Akt pathways
mediated the IRP1 down-regulation induced by BDNF and GDNF. In
the presence of these signaling inhibitors, BDNF- and GDNF-induced
down-regulation of the DMT1 + IRE protein (Fig. 6B,E), and mRNA
(Fig. 6C,F) was completely abrogated. Remarkably, although IRP1 levels
were at basal levels in the PD98059 + BDNF and PD98059 + GDNF
groups, the mRNA expression of DMT1 + IRE was even higher
compared with the control condition (Fig. 6C,F). We propose that
there may be additional transcriptional mechanism participating in
the regulation of DMT1 + IRE rather than IRP1 alone. (See Fig. 7.)
4. Discussion
In the present study, we demonstrated the potential of two
established NTFs, BDNF and GDNF, to act directly on primary cultured
VM neurons to protect these neurons against 6-OHDA-induced iron ac-
cumulation. In 1954, Cohen and colleagues [43] discovered the ﬁrst NTF
nerve growth factor (NGF) acting on nerve cells; afterwards a large
number of NTFs and their receptors, which playmultiple roles in the de-
veloping and mature CNS, were identiﬁed. BDNF and GDNF are types of
nutritional factors that are widely distributed in the brain and known to
be important for DAergic neuron survival during development and in
adulthood. Recently, GDNF has been suggested as the most potent tro-
phic factor for DAergic neurons both in vitro and in vivo [44]. Current
strategies for exploring alternative or supplementary therapeutic
strategies for PD include the evaluation of neurotrophic factors for
DAergic neurons.One study showed that treatment with NGF, another member of
neurotrophin family, induced a signiﬁcant decrease in DMT1 and TfR1
expression in PC12 cells [45]. However, controversial data have been re-
ported in PC12 cell cultures subjected to NGF [46,47]. The PC12 cell line
belongs to an adrenergic neural tumor pheochromocytoma cell line and
has the ability to proliferate and differentiate, implying that this cell line
is different from mature neurons in some aspects of cell metabolism,
such as iron needs. NTFs have been shown to protect neurons against
oxidative stress by inducing an increase in the activities of antioxidant
enzymes and modulate the expression of apoptosis-related proteins in
a pro-survival manner [37]. However, knowledge of the relationship
between NTFs and iron homeostasis crosstalk is unclear at best.
6-OHDA is a classical neurotoxin for PD models, and we previously
observed that 6-OHDA administration increased cellular iron up-take
in vitro. In the present study, we used primary cultured VM neurons
to test whether BDNF and GDNF could modulate intracellular iron
metabolism. We found that pre-incubation with BDNF (10 ng/ml) or
GDNF (10 ng/ml) for 4 h prior to 6-OHDA (10 μM) treatment blocked
6-OHDA enhanced ferrous iron inﬂux. In this manner, these two NTFs
could protect VM neurons against 6-OHDA-induced iron accumulation.
These data suggest that modulation of iron metabolism may provide a
novel mechanism by which BDNF and GDNF participate in the neuro-
protective effect.
Iron accumulateswith aging andhas been linked to several neurode-
generative diseases, especially PD [48,49]. An approximate 25% to 100%
increase in SN iron levels in patients with PD compared with normal
controls has been observed [50]. Previous studies have shown that in
the SNpc of PD patients and theMPTP-lesionedmousemodel, increased
DMT1 + IRE expression is associated with local iron accumulation and
DAergic neuron degeneration. In Belgrade rats andmk/mkmice, studies
have shown less iron accumulation and a lower susceptibility in DMT1
mutant DAergic neurons after a Parkinsonian toxin injection [16,51].
These data support the importance of DMT1 in iron-mediated neurode-
generation in PD. As we expected, the alleviation of 6-OHDA-induced
iron accumulation by BDNF and GDNF was mediated by DMT1, as indi-
cated by the result that BDNF or GDNF treatment alone down-regulated
DMT1+ IRE protein andmRNA levels, although 10 ng/ml is higher than
the physiological concentration of these neurotrophic factors. In other
words, these trophic factors were able to decrease iron uptake in the ab-
sence of the toxin. These results indicate that under normal conditions,
these trophic factors may be valuable regulators of iron metabolism
(e.g., they could down-regulate DMT1 and inhibit excess iron uptake).
In the present study, we focus on the healing properties of BDNF and
GDNF. Although lowBDNF andGDNF concentrations under physiological
conditions may mediate a relatively minor regulation of iron metabo-
lism, these brain neurotrophic factorsmay be used as a therapeutic strat-
egy to block aberrant iron uptake in the diseased state. Our previous
publication revealed that neuroprotective agents, such as ginsenoside-
Rg1, could protect MPP+-treated MES23.5 cells via attenuating DMT1
Fig. 5. BDNF and GDNF induced the phosphorylation of ERK1/2 and Akt in VM neurons. A, C, E, G: Western blots analysis of ERK1/2 and Akt phosphorylation in cultured DIV6 VM neurons exposed to 10 ng/ml BDNF or GDNF for the indicated times.
Signiﬁcantly increased levels of phosphorylated ERK1/2 within 0.5 h after BDNF administration were observed; the phospho-ERK1/2 level was gradually restored but remained above basal levels at 4 h. Phosphorylated Akt expression was similar to
that of phosphorylated ERK1/2. Maximum activation of ERK1/2 was also achieved within 0.5 h after GDNF treatment; however, the response was weaker compared with that in cells with BDNF exposure. GDNF also induced Akt phosphorylation at
0.5 h; however, the levels had returned to basal levels at 4 h. Each bar represents themean± S.E.M of four independent experiments. ⁎P b 0.05, ⁎⁎P b 0.01, compared with 0 h. B, D, F, H: Double immunoﬂuorescence labeling also showed phospho-
ERK1/2 andphospho-Akt inMAP2-positive neuronswith BDNF andGDNF treatment for 0.5 h. Pre-incubationwith theMEK inhibitor PD98059 (5 μM)or the PI3K inhibitor LY294002 (2.5 μM) for 0.5 h fully abolished BDNF- andGDNF-induced ERK1/2













Fig. 6.MEK/ERK and PI3K/Akt signaling pathwaysmediated IRP1 and DMT1+ IRE regulation by BDNF and GDNF. Primary cultured VMneurons were treated for 30min with either 5 μM
PD98059 or 2.5 μM LY294002 before 10 ng/ml BDNF or GDNF incubation for another 24 h.Western blotting and real-time PCR were conducted to investigate the expression of IRP1 and
DMT1 + IRE. A and D: Pharmacological inhibitors of the MEK/ERK or PI3K/Akt pathways fully blocked the BDNF- or GDNF-induced down-regulation of IRP1. B and E: Pharmacological
inhibitors of the MEK/ERK or PI3K/Akt pathways abolished the BDNF- or GDNF-induced down-regulation of DMT1+ IRE. β-actin was used as a loading control. C and F: In the presence
of PD98059 or LY294002, the BDNF- andGDNF-induced down-regulation of DMT1+ IREmRNAwas completely abrogated. ThemRNAexpression of DMT1+ IREwas even reversed in the
groups pretreated with PD98059. Each bar represents themean± S.E.M. of four independent experiments. ⁎P b 0.05, ⁎⁎P b 0.01, compared with control, #P b 0.05, ##P b 0.01, compared
with the BDNF or GDNF group.
2973H.-Y. Zhang et al. / Biochimica et Biophysica Acta 1843 (2014) 2967–2975up-regulation [52]. These results combined with the present study sug-
gest a crucial role for DMT1 in the modulation of iron metabolism,
which is regulated by BDNF and GDNF.
Most cellular iron transporters can be regulated at both the tran-
scriptional and post-transcriptional levels. Iron-regulatory proteins
(IRP1 and IRP2) can translationally regulate proteins involved in iron
storage (ferritin), acquisition (TfR1, DMT1 + IRE) and export
(ferroportin 1) by binding to iron-responsive elements (IREs) present
in the untranslated regions (UTR) of their respective mRNAs [53,54].
IRPs bind to IREs located in the 3’-UTR of DMT1 + IRE mRNA, thereby
stabilizing it against endonucleolytic cleavage and thus increasing the
uptake of NTBI. In this report, we present data demonstrating that the
down-regulation of DMT1 + IRE in VM neurons is consistent with de-
creased IRP expression after BDNF and GDNF incubation. Pretreatment
with BDNF and GDNF could also abolish the 6-OHDA-induced up-
regulation of IRP1, in accordance with the expression of DMT1 + IRE.
In parallel with DMT1 + IRE, 6-OHDA-induced dysregulation of TfR1
was blocked by BDNF and GDNF treatments. These results suggest that
both NTFs may participate in the regulation of iron transport in primary
cultured VM neurons by directly inﬂuencing the expression of IRP1.
The intracellular mechanisms of BDNF and GDNF required for IRP1
down-regulation must be elucidated. Mature BDNF binds with
picomolar afﬁnity to its speciﬁc TrkB [55]. Upon ligand binding, Trk
autophosphorylates tyrosine residues and stimulates intracellular
signaling pathways by activating a variety of enzymes and effectors, in-
cluding phospholipase C-γ (PLC-γ), PI3K, and MEK [56]. GDNF belongs
to the transforming growth factor-β (TGF-β) superfamily. By binding
to amulticomponent receptor complex termed GFRα, GDNF aggregates
two rearrangedmembrane Ret proteinmolecules and triggers a numberof intracellular signaling cascades, including the MAPK and PI3K
pathways [57]. Both the MEK/ERK and PI3K/Akt pathways have multi-
ple effects on neuronal survival [58]. Our western blot and double im-
munoﬂuorescence labeling data demonstrated rapid and prolonged
activation of ERK1/2 and Akt in VMneurons after BDNF and GDNF treat-
ment. Thus, we speculate an obligate requirement for ERK1/2 and Akt
activation in the negative regulation of IRP1. Consistentwith our results,
a recent study showed that lead (Pb)-induced activation of ERK1/2 in
the vascular endothelium in vitro may participate in IRP1 protein
down-regulation [59]. To conﬁrm our hypothesis, we measured the ef-
fects of an MEK inhibitor (PD98059) and PI3K inhibitor (LY294002)
on IRP1 and DMT1 + IRE levels. The inhibition of the MEK/ERK and
PI3K/Akt pathways was effective in attenuating the down-regulation
of IRP1 and sequent expression of DMT1 + IRE induced by BDNF and
GDNF, suggesting that these pathways are involved in the regulation
of iron homeostasis after NTF treatment. Remarkably, although IRP1
was expressed at basal levels in BDNF- and GDNF-treated cells by pre-
treatment with PD98059, DMT1 + IRE mRNA expression was up-
regulated, indicating a direct modulation of the MAPK pathway in
BDNF- and GDNF-regulated DMT1 mRNA expression. Further work is
needed to elucidate this mechanism.
In conclusion, BDNF andGDNF protect VMneurons against 6-OHDA-
induced iron accumulation through down-regulation of IRP1, which
post-transcriptionally regulates DMT1 + IRE expression. Both NTFs
activated the ERK and Akt signaling pathways, which may participate
in these effects. These ﬁndings of the speciﬁc interaction between
BDNF, GDNF and iron homeostasis provide novel insights into iron
homeostasis in the SN and may have implications for therapeutic
strategies for treating PD.
Fig. 7. Schematic diagram illustrating the signal transduction pathway involved in BDNF- and GNDF-mediated DMT1 + IRE expression. BDNF/GDNF-induced activation of TrkB or GFRα
results in signal propagation through ERK1/2 and Akt, leading to the down-regulation of IRP1, thereby regulating the expression of DMT1 + IRE post-transcriptionally. In addition, other
transcriptional regulatory mechanisms may be involved in the BDNF- and GDNF-related MEK/ERK pathway of direct regulation of DMT1 + IRE.
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